Business Wire

REPLY

Share
Solidsoft Reply Spearheads Ground-breaking Migration of Finland’s National Medicines Verification System

Solidsoft Reply, a Reply Group company specialising in creating Microsoft Azure cloud-based enterprise solutions, has successfully migrated Finland's National Medicines Verification System to its National Blueprint solution. National Blueprint Solution is Solidsoft Reply's Own National Verification System - A system built on Microsoft Azure cloud technology to verify medicines in accordance to the EU Falsified Medicines Directive (FMD). This notable accomplishment marks a pioneering step for the European Medicines Verification System (EMVS).

Over four years' worth of data, comprising over 500+ million medicines pack records, was meticulously migrated. This complex 10-month project required detailed planning and collaborative engagement with the Finnish Medicines Verification Organisation (FiMVO). It involved the development of a fully validated migration toolset, numerous workshops for Finnish IT suppliers, and documentation on how data is transitioned. This ensured a secure and seamless transition with full traceability of its data for auditing purposes.

David Eccles, Partner at Solidsoft Reply, remarked, “This successful migration is not just a remarkable achievement but also a testament to our engineering expertise and collaborative ethos at Solidsoft Reply. Our partnership with FiMVO was instrumental in overcoming the technical challenges, setting a new standard in the EMVS ecosystem.”

Maija Gohlke General Manager at the Finnish Medicines Verification Organisation FiMVO (Suomen Lääkevarmennus Oy) remarked “the project was handled very professionally and that reflects on the smooth execution of this project, a first of its kind and of a huge magnitude, with so many connection points in the supply chain. The knowledge, dedication and flexibility of the Solidsoft Reply team exceeded our expectations.”

This marks the first-ever migration of a national medicines verification system within the EMVS ecosystem between blueprint providers; and is particularly significant in the context of healthcare and pharmaceuticals, where accuracy, data integrity, and security are paramount. This project is a prime example of Solidsoft Reply’s dedication to enhancing healthcare systems through advanced technology, significantly contributing to the safety and efficacy of healthcare delivery.

Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. Reply is a network of highly specialised companies supporting key European industrial groups operating in the telecom and media, industry and services, banking, insurance and public administration sectors in the definition and development of business models enabled for the new paradigms of big data, cloud computing, digital media and the Internet of Things. Reply services include: Consulting, System Integration and Digital Services. www.reply.com

Solidsoft Reply
Solidsoft Reply is the Reply group company creating enterprise strength solutions utilising the Microsoft Azure cloud platform. A global award-winning Microsoft Solutions Partner, Solidsoft Reply is recognised by the Pharmaceutical & Healthcare industries as being one the of leading delivery partners in Verification and Traceability systems world-wide. www.solidsoft.reply.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240201923213/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Murata HCR Redefines Automotive Timing Devices With the Total Frequency Tolerance of ±40PPM Under -40°C to +125°C Operation14.11.2024 03:00:00 CET | Press release

Murata Manufacturing Co., Ltd. (TOKYO:6981) (ISIN:JP3914400001) unveils a cutting-edge electronic timing device featuring exceptional accuracy ±40ppm and reliability even in wide-temperature -40°C to +125°C conditions. By addressing the limitations of current timing components in automotive electronic systems, it enhances the design and deployment of next-generation In-Vehicle Networks (IVN), wireless communication, and Advanced Driver Assistance Systems (ADAS) functions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241113670074/en/ Murata Manufacturing Co., Ltd.: The new Timing Devices, XRCGE_M_F series (Photo: Business Wire) As the automotive industry continues to pursue greater integration and electronic downsizing to address the expanding number of critical electronic systems, the performance requirements for components are growing. In order to achieve tighter packaging without compromising accuracy, it is now necessar

SBC Medical Group Holdings Inc. Reports Third Quarter 2024 Financial Results13.11.2024 22:59:00 CET | Press release

SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), a global owner, operator and provider of management services and products to cosmetic treatment centers, today announced its unaudited financial results for the third quarter ended September 30, 2024. Third Quarter 2024 HighlightsTotal revenues for the three months ended September 30, 2024 were $53 million, representing an increase of 12% from $47 million in the same quarter of 2023. Total revenues for the nine months ended September 30, 2024 was $160 million, representing an increase of 23% from $131 million in the same period of 2023. Income from operations for the three months ended September 30, 2024 was $13 million, representing a decrease by 31% from the same quarter in 2023. This result was impacted by $12.8 million of stock-based compensation expense related to the Company’s listing process. Income from operations for the nine months ended September 30, 2024 was $65.5 million, representing an increase of

Altasciences’ Commitment to Supporting Pharma and Biotech With Comprehensive Bioanalytical Services13.11.2024 18:00:00 CET | Press release

Altasciences, a trusted drug development research partner for over 30 years, continues its commitment to providing world-class bioanalytical services. This core business supports both preclinical and clinical studies conducted at Altasciences’ facilities, while also offering an extensive standalone solution to meet the diverse needs of clients. By delivering high-quality, flexible bioanalytical services, Altasciences remains dedicated to advancing drug development and empowering clients across every phase of research. For three decades now, Altasciences has taken pride in evolving their solutions to meet the needs of pharmaceutical and biotechnology companies of all sizes, including the expansion of their labs in Seattle, WA, Columbia, MO, and Laval, Québec. Their three state-of-the-art bioanalytical laboratories feature mirrored operations and uniform protocols to maintain consistency and quality across client projects, ensuring reliable, high-quality data regardless of location. This

Medidata Secures Highest Leadership Position in Everest Group’s First Life Sciences Clinical Trial Management System Products PEAK Matrix® Assessment13.11.2024 15:30:00 CET | Press release

Medidata, a Dassault Systèmes brand and the leading provider of clinical trial solutions to the life sciences industry, has been recognized as a leader in Everest Group's first-ever Life Sciences Clinical Trial Management System Products PEAK Matrix® Assessment 2024. The report assessed 13 providers based on the market impact of their products and their ability to deliver successful, high-quality offerings. Medidata Rave CTMS leads the industry by providing seamless, real-time patient data outputs that transform enrollment tracking and enable faster, data-driven decisions. Offering instant visibility for study teams, Rave CTMS streamlines collaboration, eliminates manual data entry, and accelerates trial timelines with exceptional accuracy. “We are honored to be recognized as the highest leader in CTMS by Everest Group,” said Tom Doyle, chief technology officer, Medidata. “This accolade underscores our unwavering commitment to transforming research and reaffirms our strategy to deliver

China Moutai Showcases Ecology Promotion Practices at the China Pavilion During COP2913.11.2024 15:05:00 CET | Press release

At a side event titled "Ecological Civilization and Beautiful China Practices" during the 2024 UN Climate Change Conference (COP29) in Baku, Azerbaijan, China Moutai showcased its commitment to ecological sustainability and called for greater attention to climate change. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241113718721/en/ Li Wang, General Manager of China Moutai Group, presented at the side event in Baku. (Photo: Business Wire) Li Wang, General Manager of China Moutai Group, emphasized that Chinese modernization is rooted in achieving harmony between humanity and nature. She said that as a representative of China’s liquor industry, Moutai has embraced the principle that "lucid waters and lush mountains are invaluable assets." This philosophy underscores the company’s approach to modernization, which prioritizes environmental stewardship. Wang highlighted Moutai Group’s dedication to leveraging regional ecological

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye